Cochlear Limited announced that, it has received FDA clearance for the Cochlear™ Osia® 2 System. The system is indicated and approved in the US for adults and children (12 years and older) with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness. The Osia 2 System is the world's first active osseointegrated steady-state implant, using digital piezoelectric stimulation to bypass damaged areas of the natural hearing system and send sound vibrations directly to the cochlea. Cochlear will commence the commercial rollout of the Osia 2 System in the US during the second half of fiscal 2020. Availability in other countries will be subject to regulatory approvals.